Clinical Trial Update: Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and dose-finding study of DTX301 (scAAV8OTC) for adults with late-onset Ornithine Transcarbamylase deficiency has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ornithine Transcarbamylase Deficiency

Drugs mentioned

• DTX301

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Ornithine Transcarbamylase (OTC) Deficiency | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-23